Table 1. Drug Indications Included in Analysis With Baseline Demographics Among SEER-Medicare Patients and Clinical Trial Intervention Arm.
| Year of FDA approval | Drug | FDA indicationa | SEER-Medicare/trial intervention arm | Modified Charlson comorbidity index, (range, 0-1), No. (%) | |||
|---|---|---|---|---|---|---|---|
| Sample size | Age, median (IQR)/ y | No. (%) | |||||
| White race | Male sex | ||||||
| 2008 | Pemetrexed | NSCLC, first line | 720/862 | 70 (67-73)/61 | 605 (84.0)/672 (78.0) | 382 (53.1)/603 (70.0) | 653 (90.7) |
| 2009 | Everolimus | Kidney cancer | 105/272 | 70 (66-75)/61 | 84 (80.0)/NR | 64 (61.0)/212 (77.9) | 86 (81.9) |
| 2009 | Pazopanib | Kidney cancer | 295/290 | 72 (67-78)/59 | 245 (83.0)/252 (86.9) | 189 (64.1)/197 (67.9) | 235 (79.7) |
| 2009 | Pemetrexed | NSCLC, maintenance | 2192/359 | 73 (69-77)/61 | 1885 (86.0)/337 (93.9) | 1096 (50.0)/201 (56.0) | 1901 (86.7) |
| 2010 | Erlotinib | NSCLC, maintenance | 208/438 | 71 (67-76)/60 | 156 (75.0)/368 (84.0) | 114 (54.8)/320 (73.1) | 165 (79.3) |
| 2010 | Cabazitaxel | Prostate cancer | 220/378 | 71 (68-76)/68 | 187 (85.0)/325 (86.0) | 220 (100.0)/378 (100.0) | 207 (94.1) |
| 2010 | Eribulin | Breast cancer | 43/508 | 68 (66-73)/55 | 36 (83.7)/472 (92.9) | 0/0 | 41 (95.3) |
| 2010 | Trastuzumab | Gastric cancer | 43/294 | 71 (66-74)/59 | 36 (83.7)/115 (39.1) | 32 (74.4)/226 (76.9) | 38 (88.3) |
| 2010 | Sipuleucel-T | Prostate cancer | 331/341 | 73 (69-79)/72 | 285 (86.1)/303 (88.5) | 331 (100.0)/341 (100.0) | 290 (87.6) |
| 2011 | Everolimus | Pancreatic NET | 53/207 | 72 (68-76)/58 | 47 (88.7)/155 (74.9) | 30 (56.6)/110 (53.1) | 45 (84.9) |
| 2011 | Abiraterone | Prostate cancer, prior docetaxel | 122/797 | 72 (68-75)/69 | 78.7 (96.0)/NR | 122 (100.0)/797 (100.0) | 115 (94.3) |
| 2011 | Vemurafenib | Melanoma | 84/337 | 70 (67-77)/56 | 46 (97.6)/199 (99.1) | 82 (54.8)/334 (59.1) | 75 (89.3) |
| 2011 | Cetuximab | Head and neck cancer | 55/222 | 68 (67-74)/56 | 87.3 (48)/NR | 83.4 (46)/89.2 (198) | 46 (83.6) |
| 2011 | Ipilimumab | Melanoma | 32/137 | 73 (68-78)/56 | 32 (100.0)/129 (94.2) | 22 (68.8)/84 (61.3) | 26 (81.3) |
| 2012 | Everolimus | Breast cancer | 97/485 | 71 (68-77)/62 | 79 (81.4)/359 (74.0) | 0/0 | 91 (93.8) |
| 2012 | Axitinib | Kidney cancer | 88/361 | 71 (67-76)/61 | 74 (84.0)/278 (77.0) | 60 (68.2)/264 (73.1) | 75 (85.2) |
| 2012 | Nab-paclitaxel | NSCLC | 179/521 | 75 (68-80)/60 | 141 (78.8)/417 (80.0) | 104 (58.1)/391 (75.0) | 145 (81.0) |
| 2012 | Enzalutamide | Prostate cancer | 215/800 | 72 (68-76)/69 | 215 (78.1)/800 (93.0) | 215 (100.0)/800 (100.0) | 192 (89.3) |
| 2012 | Abiraterone | Prostate cancer | 742/546 | 74 (69-80)/71 | 556 (74.9)/NR | 742 (100.0)/546 (100.0) | 621 (83.7) |
| 2012 | Regorafenib | Colorectal cancer | 295/505 | 70 (66-74)/61 | 224 (75.9)/394 (78.0) | 162 (54.9)/313 (61.9) | 270 (91.5) |
| 2012 | Cetuximab | Colorectal cancer | 280/316 | 70 (67-74)/61 | 227 (81.1)/NR | 174 (62.1)/196 (62.0) | 248 (88.6) |
| 2012 | Pertuzumab | Breast cancer | 88/402 | 70 (66-76)/54 | 67 (76.1)/245 (60.9) | 0/0 | 76 (86.4) |
| 2012 | Ziv-aflibercept | Colorectal cancer | 79/612 | 73 (68-76)/61 | 43 (67.1)/367 (90.0) | 53 (54.4)/551 (60.0) | 71 (89.9) |
| 2013 | Trastuzumab emtansine | Breast cancer | 53/495 | 71 (66-77)/53 | 43 (81.1)/356 (71.9) | 0 (0)/1 (0.2) | 48 (90.6) |
| 2013 | Dabrafenib | Melanoma | 51/187 | 73 (67-79)/53 | 50 (98.0)/187 (100) | 30 (58.8)/112 (59.9) | 44 (86.3) |
| 2013 | Nab-paclitaxel | Pancreatic cancer | 1019/431 | 73 (68-77)/62 | 866 (85.0)/379 (87.9) | 530 (52.0)/246 (57.1) | 853 (83.7) |
| 2013 | Afatinib | NSCLC | 71/230 | 77 (71-84)/62 | 51 (71.8)/62 (27.0) | 19 (26.8)/83 (36.1) | 64 (90.1) |
| 2013 | Erlotinib | NSCLC | 1032/86 | 77 (67-76)/65 | 65.0/90.7 | 299 (29.0)/28 (32.6) | 866 (83.9) |
| 2013 | Bevacizumab | Colorectal cancer | 386/409 | 71 (67-75)/63 | 305 (79.0)/NR | 216 (56.0)/266 (65.0) | 352 (91.2) |
Abbreviations: FDA, US Food and Drug Administration; IQR, interquartile range; nab, nanoparticle albumin-bound; NET, neuroendocrine tumor; NR, not reported in clinical trial publication, FDA package insert, or ClinicalTrials.gov; NSCLC, non–small cell lung cancer; SEER, Surveillance, Epidemiology, and End Results.
a
Complete FDA-approved indications are listed in eTable 1 in the Supplement.